<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1530</td>
<td>Sexual dysfunctions and their treatment in liver diseases</td>
<td>Jagdish RK</td>
</tr>
<tr>
<td>1541</td>
<td>Long-term liver allograft fibrosis: A review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection</td>
<td>Vij M, Rammohan A, Rela M</td>
</tr>
<tr>
<td>1550</td>
<td>Outcomes of patients with post-hepatectomy hypophosphatemia: A narrative review</td>
<td>Chan KS, Mohan S, Shelat VG</td>
</tr>
<tr>
<td>1576</td>
<td>Missed opportunities for hepatitis C treatment at a tertiary care hospital in South Australia</td>
<td>Raja SS, Edwards S, Stewart J, Huynh D</td>
</tr>
<tr>
<td>1584</td>
<td>Survival outcomes and predictors of mortality, re-bleeding and complications for acute severe variceal bleeding requiring balloon tamponade</td>
<td>Keung CY, Morgan A, Le ST, Robertson M, Urquhart P, Swan MP</td>
</tr>
<tr>
<td>1598</td>
<td>Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States</td>
<td>Alkhouri N, Aggarwal P, Le P, Payne J, Sakkal C, Polanco P, Harrison S, Noureddin M</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>1633</td>
<td>Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease</td>
<td></td>
</tr>
<tr>
<td>1643</td>
<td>Prevalence of sarcopenia using different methods in patients with non-alcoholic fatty liver disease</td>
<td></td>
</tr>
<tr>
<td>1652</td>
<td>Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B</td>
<td></td>
</tr>
<tr>
<td>1667</td>
<td>Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial</td>
<td></td>
</tr>
<tr>
<td>1678</td>
<td>Secondary sclerosing cholangitis after critical COVID-19: Three case reports</td>
<td></td>
</tr>
<tr>
<td>1687</td>
<td>Hemorrhagic colitis induced by trientine in a 51-year-old patient with Wilson’s disease waiting for liver transplantation: A case report</td>
<td></td>
</tr>
</tbody>
</table>

**CORRECTION**

Author affiliation addition: “Hepatitis B virus detected in paper currencies in a densely populated city of India: A plausible source of horizontal transmission?”

Das P, Supekar R, Chatterjee R, Roy S, Ghosh A, Biswas S
ABOUT COVER
Editorial Board Member of World Journal of Hepatology, Dmitry Victorovich Garbuzenko, MD, PhD, DSc (Med), Professor, Department of Faculty Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia. garb@inbox.ru

AIMS AND SCOPE
The primary aim of World Journal of Hepatology (WJH, World J Hepatol) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING
The WJH is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for WJH as 0.52. The WJH’s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Editorial Office Director: Xiang Li.

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Nikolaos Pyrsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
August 27, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/GerInfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Sexual dysfunctions and their treatment in liver diseases

Rakesh Kumar Jagdish

Abstract

Sexual dysfunction (SD) is a prevalent but very commonly ignored aspect in the treatment of liver diseases and cirrhosis. The etiology of SD is multifactorial and therefore treatment strategies are complex, especially in females. Phosphodiesterase inhibitors are useful and effective in erectile dysfunction in males but in females, no single drug is available for SD, therefore multimodal treatment is required depending upon the cause. The foremost and fundamental requirement in both genders is to be stress-free and have adequate control of liver diseases. Improved quality of life is helpful in improving SD and vice versa is also true. Therefore, patients suffering from liver diseases should come forward and ask for treatment for SD, and physicians should actively enquire about SD while history taking and evaluating these patients. SD results in deterioration of quality of life, and both are modifiable and treatable aspects of liver diseases, which are never addressed actively, due to social taboos and fears of SD treatment in the presence of liver diseases. The diagnosis of SD does not require costly investigations, as the diagnosis can be established based on validated questionnaires available for both genders, therefore detailed targeted history taking using questionnaires is essential. Data are emerging in this area but is still at an early stage. More studies should be dedicated to SD in liver diseases.

Key Words: Sexual dysfunction; Erectile dysfunction; Female sexual function index; International index of erectile function; Phosphodiesterase inhibitors; Hepatic venous pressure gradient

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Liver diseases and cirrhosis related sexual dysfunction (SD) is present in a significantly high proportion of both genders but is often underestimated, ignored, or overlooked. Due to its multifactorial causations, detailed history taking, examination, and addressing potential causes are required for the diagnosis and management of SD. More randomized controlled trials should be planned for both genders regarding the newer treatment options.

INTRODUCTION
Sexual dysfunction (SD) in liver diseases has a multifactorial origin, and this is often the most ignored aspect in both male and female patients. This review attempts to break the myths and social taboos on the sexual aspect, and the quality of life in patients with liver diseases, with simplified diagnostic criteria, common causes, treatment, and other management options. The aim is to provide support for the sexual life of liver disease patients as SD can have a negative effect on the quality of life and can cause psychological issues such as less emotional satisfaction and general unhappiness and depression [1]. It should be noted that, infertility issues related to cirrhosis are separate to SD, therefore are not discussed in this review.

SEXUAL DYSFUNCTIONS
In men, SD is categorized into disorders of desire (low libido), arousal (erectile dysfunction), or orgasm (premature or delayed ejaculation, or anorgasmia), according to their occurrence in the cycle of sexual response[2]. The most common presentations are premature ejaculation, which is arbitrarily defined as ejaculation within one minute (60 s) of vaginal penetration, or erectile dysfunction (ED), which is the inability to obtain and maintain a penile erection in order to achieve satisfactory sexual activity. ED is considered to be common in cirrhosis; predominantly due to endocrine dysfunction and sarcopenia. There is a paucity of data on the precise prevalence of and predictive factors for ED in cirrhosis. Phosphodiesterase type 5 (PDE5) inhibitors were found to be useful for ED in the non-cirrhotic and cirrhotic population in a recent randomized controlled trial (RCT) of tadalafil in cirrhotics [1].

In females, SD is more complex and predominantly manifests as low libido, vaginal dryness, dyspareunia, orgasm inability, or menstrual abnormalities [3].

INCIDENCE AND PREVALENCE OF SD
Patients with cirrhosis have a high prevalence of ED ranging from 25% to 92% in various studies [4-8] as shown in Table 1. In a recent RCT[1], it was found to be 70.3%, whereas in females, studies on prevalence are limited, but it has been shown that the prevalence of abnormal menstrual cycles was seen in 58%, decreased sexual interest in 42%, and no sexual activity in 56% of females [3,9]. In a study of women with non-alcoholic liver disease, reduced sexual desire was found in 33%, reduced arousal in 18%, not feeling orgasm in 25%, and dyspareunia in 21%, related to decreased vaginal lubrication. Prospective studies are needed especially in female patients.

RISK FACTORS CONTRIBUTING TO ED IN LIVER DISEASES IN BOTH GENDERS
The causation of SD in both genders is multifactorial, although there are only a few studies in females as compared to males. Female sexual function involves hormonal, neurological, vascular, psychological, and emotional aspects. Dysfunction may be triggered or maintained by any of these, or by the interplay between them. The hormonal interplay is grossly disturbed in chronic liver diseases (CLD) along with multiple other non-hormonal factors contributing to SD in CLD. Possible contributing factors to SD in both genders [10,12] in liver diseases are shown in Figure 1.
Table 1 Erectile dysfunction prevalence studies

<table>
<thead>
<tr>
<th>Disease etiology and age</th>
<th>Prevalence</th>
<th>Study</th>
<th>Ref.</th>
<th>Journal, year</th>
<th>Method used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis of liver</td>
<td>70.3%</td>
<td>Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: A randomized placebo controlled trial</td>
<td>Jagdish et al[1], India</td>
<td>Hepatology International, 2021</td>
<td>IIEF-5</td>
</tr>
<tr>
<td>Chronic viral liver diseases</td>
<td>60%, age &lt; 50 years, 88% age &gt; 50 years. ED</td>
<td>Erectile dysfunction in patients with chronic viral liver disease: Its relevance to protein malnutrition</td>
<td>Toda et al[4], Japan</td>
<td>Gastroenterology, 2005</td>
<td>IIEF-5 and medical outcomes study short form 36 (SF-36)</td>
</tr>
<tr>
<td>Hepatitis B-aged 40-59 yr (SD 50.2 ± 5.7)</td>
<td>Total 24.6%, (CHB-8.6%, HBV-LC-41.2%)</td>
<td>Erectile dysfunction in patients with liver disease related to chronic hepatitis B</td>
<td>Kim et al[5], Korea</td>
<td>Clinical and Molecular Hepatology, 2015</td>
<td>Erectile function of patients was evaluated by the Korean version of IIEF-5</td>
</tr>
<tr>
<td>Hepatitis C, age &lt; 20-80yr (SD; 50 ± 17.9yr)</td>
<td>30%</td>
<td>Erectile dysfunction in patients with chronic hepatitis C virus infection</td>
<td>Hunter et al[6], Egypt</td>
<td>Arab J Gastroenterol, 2014</td>
<td>An Arabic validated version of the five-item IIEF-5</td>
</tr>
<tr>
<td>Alcoholic liver diseases (age &lt; 56 yr)</td>
<td>61%</td>
<td>Sexual dysfunction in men with alcoholic liver cirrhosis. A comparative study</td>
<td>Jensen et al[7], UK</td>
<td>Liver, 1985</td>
<td>All groups had a significantly (P less than 0.025) raised prevalence of sexual dysfunction when compared to men without chronic disease</td>
</tr>
<tr>
<td>Chronic liver disease (mean age 54.8 ± 10.8 yr)</td>
<td>50.6%</td>
<td>Assessment of sexual function in patients with chronic liver disease</td>
<td>Simsek et al[8], Turkey</td>
<td>Int J Impot Res, 2005</td>
<td>International index of erectile function</td>
</tr>
</tbody>
</table>

CHB: Chronic hepatitis B; ED: erectile dysfunction; HBV: Hepatitis B virus; IIEF-5: International index of erectile function.

**Non hormonal causes**

Reduced quality of life due to depression (which can affect all phases of sexual function), anxiety, and stress are important factors. ED itself is associated with poor health-related quality of life[11,13] and depressive symptoms in both cirrhotic and non-cirrhotic patients.

Low serum albumin is a significant factor in ED and a low international index of erectile function (IIEF) score in liver diseases has been reported in multiple studies[4]. Hypoalbuminaemia results in water retention and loss of muscle volume which decreases sexual desire, and physical function. The ratio of albumin-bound to free testosterone may be influenced by decreased production of albumin which might then influence sexual desire and sleep-related erection. A study by Paternostro et al[14] showed that liver dysfunction, diabetes mellitus, hypertension, and high hepatic venous pressure gradient (HVPG), are key risk factors for ED in male cirrhotic patients.

Sarcopenia, as measured by the appendicular skeletal muscle index, was found to be associated with ED in a recent study[11,12]. This appears to be clinically significant as patients with low muscle mass are more likely to have low albumin, low power, frailty, and poor sexual performance. The concept of sexual frailty is similar to frailty in other organ systems. Musculoskeletal health needs to be highlighted in the evaluation of cirrhosis along with sexual health. More randomized trials should be conducted to understand the pathogenesis and underlying mechanisms and possible treatment options in this area.

Clinical features of hypogonadism, such as ED, infertility, decreased libido, and testicular atrophy, are often seen in patients with advanced liver disease, and it has been shown that the severity of liver cirrhosis correlates with the degree of ED[4].

**Effects of drugs**: Propranolol has a negative impact on erectile function, which is widely used to treat portal hypertension[15,16], but the doses which are required to cause ED are higher than the doses commonly used in CLD. Although Paternostro et al[14] found that beta-blockers were not associated with ED, beta-blockers generally cause vasodilation, and inhibit the release of renin, angiotensin II, and aldosterone production. These effects result in decreased adrenergic outflow from the sympathetic nervous system, resulting in SD[17]. However, a large meta-analysis[18] did not support the notion that beta-blocker (BB) therapy is associated with a relevant risk of SD, which was also supported by a recent RCT[1]. Spironolactone, an anti-mineralocorticoid and aldosterone antagonist, has anti-androgenic properties and can cause decreased libido and SD[16,17].

**Hormonal causes (sex hormones)**

Studies have shown that free and albumin-bound testosterone, rather than total testosterone concentration, correlated positively with sexual desire and sleep-related erection in healthy subjects[19]. Therefore, it is possible that the reduced production of albumin may affect the ratio of free testosterone
to albumin-bound testosterone, as well as the total amount of testosterone, possibly modifying cell or tissue response to this sex hormone in cirrhotic patients. Sex hormone-binding globulin (SHBG) levels [20,21] are elevated in patients with cirrhosis due to increased hepatic production, but the pathogenesis of this remains unclear. Rising levels of SHBG have been shown to correlate with the severity of fibrosis in patients with chronic liver disease [22]. Due to the binding of testosterone to SHBG, the total serum testosterone value can remain normal or occasionally be raised in this patient group, despite reduced levels of free (presumed biologically active) testosterone [23].

**ASSESSMENT OF SD**

There are various well-validated questionnaires for SD and its risk factor assessment. The female sexual function index (FSFI) and the IIEF in males are the two most validated objective tools for SD severity assessment, with various domains and questions pertaining to each domain, which are then scored into numerical values[10] (Figure 2).

**Females**

The FSFI: A total of six domains are assessed, with a total set of 19 questions. All domains have the highest score of 6, and the total maximum score is 36, where a score of 0 represents no sexual activity during the preceding month. An overall score below 26.55 is indicative of female SD[10,24]. Female sexual dysfunction (FSD) is classified into three main clinical types. For each diagnosis, the disorder is experienced at least 75% of the time for at least six months (except for medication-induced FSD), resulting in significant distress. The three types, some or all of which may be present, are (1) Sexual interest/arousal disorder, which is defined as reduced or absent sexual interest, responsiveness, erotic thoughts and sexual pleasure; (2) Female orgasmic disorder (absence, infrequency, reduction, delay of orgasm); and (3) Genito-pelvic pain/penetration disorder (difficulty in vaginal penetration, marked vulvovaginal or pelvic pain during penetration, fear or anxiety about pain in anticipation of, during, or after penetration, and tightening or tensing of pelvic floor muscles during attempted penetration).

**Males**

The IIEF[25]: A 15-item questionnaire that assesses five domains of male sexual function using 5- to 6-point Likert scales, with 0 or 1 signifying a low frequency or ability and 5 signifying a high frequency or
Figure 2  Assessment of sexual dysfunction in liver disease.

ability. These domains include erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. The erectile function domain possible scores range from 1 to 30. The severity of ED is defined using the IIEF-EF domain’s score: 5 or lower, (no attempts at intercourse at all); 6 to 10, severe ED; 11 to 16, moderate ED; 17 to 21, mild to moderate ED; 22 to 25, mild ED; and 26 to 30, is normal erectile function\[1\]. The IIEF has also been validated in the Indian population\[26\].

Other questionnaires: The quantitative ADAM (qADAM) questionnaire\[27\] is a new tool in quantifying the severity of hypogonadism, sexual encounter profile (SEP), and Global Assessment Question for assessing sexual performance\[1\]. The total qADAM score ranges between 10 and 50, with 10 being the most symptomatic and 50 being the least symptomatic.

The SEP diaries record yes/no responses after sexual encounters. There are five questions, but two questions are most frequently used to assess SD. SEP2 is "Were you able to insert your penis into your partner’s vagina?" and SEP3 is "Did your erection last long enough for you to have successful intercourse?"

QUALITY OF LIFE IN PATIENTS WITH ED AND CIRRHOSIS

Approximately 92% of patients with cirrhosis and SD showed a significant impact on their quality of life as assessed by the SF-36 score\[28\]. Other scores related to the quality of life are the Generalized Anxiety Disorder 7 (GAD-7) questionnaire\[29\], where a GAD-7 score of ≥ 10 indicates a probable diagnosis of GAD, and the Patient Health Questionnaire (PHQ)\[30\] where a PHQ-9 score ≥ 10 is an indication of major depression. Both anxiety and depression are implicated in the causation of ED and SD. In a recent study, we have shown that treatment of ED with tadalafil results in a significant decline in the GAD-7 and PHQ-9 scores, with a significant improvement in scores of five of the eight domains of SF-36 when compared with placebo\[1\].

MANAGEMENT, CLINICAL APPROACH AND TREATMENT

Adequate management of the primary liver disease is of paramount importance, as most of the treatment targeting SD may not be feasible or even contraindicated in Child C cirrhosis\[31\]. Therefore, adequate control of liver diseases and co-morbidities is warranted. The clinical approach and treatment of SD in liver diseases are summarized in Figures 3 and 4.
**Figure 3** Clinical approach to sexual dysfunction in both genders with liver diseases.

- **Evaluation for SD**
  - Adequate treatment of primary liver diseases
  - Ask leading questions for sexual issues and psychological issues
  - Detailed targeted History and Careful Pelvic Examination
  - Relevant Investigations and use of questionnaire for assessment of SD

- **Treatment of SD**
  - Remove and treat the culprit cause of SD
  - Counselling and psychological support
  - Treatment of the underlying Liver diseases and supportive treatment for SD

- **Follow up for SD**
  - Regular follow up and support for liver diseases and sexual dysfunction (SD)

**Figure 4** Treatment of sexual dysfunction in chronic liver diseases. CLD: Chronic liver diseases; CAM: Crassulacean acid metabolism; OTC: Over the counter.

**Male:**
- Erectile Dysfunction—PDE5 inhibitors (not indicated in child C class)
  1. Sildenafil: Starting dose 25 mg, 2. Tadalafil, Dose: 10 mg, longer half life, better compliance
  3. Vardenafil, Dose: 5mg, max 10 mg
  4. Avanafil: New agent in the group, with little experience

**Females:**
- Anovulation/amenorrhea: Oral contraceptive pills/oestrogen therapy
- Menopause: Hormonal replacement therapy
- Stress: Cognitive behavioural therapy
- Reduced libido: Identify and treat depression, psychosexual support
- Reduced arousal: Lubricants and correction of coagulopathy
- Inability to orgasm: Clitoral stimulation devices and sex aids

Both male and female patients

**Counselling for partners:** Counselling for both partners to understand the facts and myths, particularly regarding liver diseases and sexual activity can be advised.
Environmental modifications: Partners may accordingly be advised to change to a suitable environment, to change positions, or poses, as per the stage of the disease. Pelvic floor exercises and general exercises may be recommended to improve frailty, including sexual frailty.

Avoid stamina supplements: Avoid complementary alternative medications, herbs, and over the counter drugs available in many countries to boost stamina. Most of these drugs have not been studied and are strictly discouraged for use as they can be harmful in the presence of liver diseases.

Female patients
Female SD is subjective dissatisfaction, the management of which can vary among patients. A single drug is not the answer to female SD in contrast to her male counterpart’s ED.

Management of female SD in cirrhotics is complex and depends on identifying and treating the predominant underlying causes, but often requires multimodality involvement for optimal results. Evaluation of the underlying causes includes a detailed history, hormonal analysis, pelvic ultrasound, gynaecological examination, and psychological evaluation, along with the status and stage of liver diseases. A new-onset SD can be a sign of advanced liver disease, coagulopathy, or other metabolic or cardiovascular disease.

Various treatment strategies are shown in Figure 3. Modifications in lifestyle are recommended, such as possible pelvic floor exercises depending on cirrhotic stage, and cessation of smoking and alcohol consumption. If it is causing poor performance, even in a passive role in sexual activity, blood transfusion or intravenous iron therapy can be used to correct anaemia. Coagulation correction and management of bleeding should be kept in mind. Forced acts may risk bleeding. Arousal enhancement strategies include relationship couples counselling, sex education using videos and educational literature, sexual positions yoga, romantic songs, romantic dressing, making the environment suitable for sexual pleasure, and increasing foreplay time. Cognitive behavioural therapy is a type of psychotherapy that helps to remove sexual inhibitions and helps in enhancing interpersonal relationships and sexual involvement. Medical devices such as clitoral therapy devices for sexual arousal and orgasmic dysfunctions can be helpful in some cases. Oestrogen is effective in the treatment of dyspareunia related to menopause. Strict contraception should be used to avoid pregnancy, as pregnancy should be planned after discussion with the treating doctor for the best outcome. Transdermal testosterone was tried in postmenopausal women with hypoactive sexual desire disorder with variable results. To date, there are no FDA-approved treatments available for FSD; thus, prospective studies and RCTs should be conducted in these patients.

SD in women after liver transplantation
Studies of liver transplant recipients have shown that 72% of females became sexually active after LT. 95% of females younger than 46 years had a regular menstrual cycle by the end of the first year of liver transplantation, but irregular bleeding and amenorrhea were present in 26% and 26%, respectively. An interval of at least 1-2 years after successful LT is recommended before considering pregnancy. Mycophenolate mofetil should be stopped before planning a pregnancy due to its teratogenicity.

Male patients
The basic mechanism of sexual arousal and further physiological changes involves nitric oxide (NO) and related mechanisms. Phosphodiesterase (PDE) inhibitors competitively bind to PDE5 and inhibit c-GMP hydrolysis, thus enhancing the effects of NO. This increase in c-GMP in smooth muscle cells results in a prolonged erection. In view of the lack of direct effect of PDE5 inhibitors on corpus cavernosum and smooth-muscle relaxation, adequate sexual stimulation is necessary for an erection to occur. Therefore, foreplay and stress relief are required. The approved agents for the treatment of ED are sildenafil, tadalafil, vardenafil, and avanafil, but tadalafil appears to be the best option due to its long half-life and flexibility in the timing of administration.

A recent RCT demonstrated that therapy with tadalafil (10 mg/d) for 12-wk significantly improved erectile function, anxiety, depression, and quality of life, and was well tolerated by men with cirrhosis (CTP score 10) and ED, with no significant side effects. It also improves depression and quality of life related to ED.

Other treatment strategies for ED in CLD
Intramuscular testosterone supplementation has been shown to be beneficial in increasing muscle mass and improving sarcopenia, which can indirectly benefit SD as sarcopenia has been shown to be associated with ED. This may help with sexual frailty. However, direct data on sexual function are not available.

Role of albumin: No direct evidence is available on the role of albumin, but it seems to be logical as it adequately controls the primary liver disease, which may help in sexual frailty. Our hypothesis suggests that reduced serum albumin may affect the ratio of free albumin to bound testosterone with a possible altered testosterone response. Therefore, improving albumin concentration might be helpful in ED and
Table 2 Studies of hepatic venous pressure gradient changes with phosphodiesterase-5 inhibitors

<table>
<thead>
<tr>
<th>HVPG change</th>
<th>Intervention</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>No significant change in HVPG</td>
<td>Tadalafil 10 mg</td>
<td>Jagdish et al[1], 2021, <em>Hept International</em></td>
</tr>
<tr>
<td>N = 10, in seven patients, HVPG decreased and in three it increased but the decrease was not significant</td>
<td>Sildenafil 30 mg</td>
<td>Clemmesen et al[43], 2008, <em>World J Gastroenterology</em></td>
</tr>
<tr>
<td>Lowers portal pressure in the acute setting by about 20%</td>
<td>75-100 mg of the phosphodiesterase-5-inhibitor udenafil</td>
<td>Kreisel et al[44], 2015, <em>Dig Liver Dis</em></td>
</tr>
<tr>
<td>Decreased HVPG in 4/5 patients</td>
<td>Vardenafil 10 mg</td>
<td>Deibert et al[45], 2006, <em>Aliment Pharmacol Ther</em></td>
</tr>
<tr>
<td>No effect on HVPG</td>
<td>Sildenafil</td>
<td>Tandon et al[46], 2010, <em>Clin Gastroenterol Hepatol</em></td>
</tr>
<tr>
<td>HVPG decrease from 10 mmHg to 7 mmHg (case report)</td>
<td>Sildenafil 20 mg bd</td>
<td>Bremer et al[47], 2007, <em>J Med Case Rep</em></td>
</tr>
<tr>
<td>HVPG decreased by 13%, and portal flow increased by 28% (case report)</td>
<td>Vardenafil</td>
<td>Deibert et al[48], 2018, <em>World J Gastroenterology</em></td>
</tr>
</tbody>
</table>

HVPG: Hepatic venous pressure gradient.

testosterone is more likely to be beneficial in patients with high albumin levels. Therefore, regular albumin therapy and high protein intake may be indirectly helpful in improving SD. This hypothesis needs to be confirmed in prospective trials.

Liver transplantation and sexual function
Improvement in SD has not been consistently reported after liver transplantation. This requires more randomized trials for a better understanding. There are a few contradictory studies; therefore, further investigation in both genders is needed. Improvement in erectile function is associated with the absence of hypogonadism before living donor liver transplant[3,10]. However, after transplantation, up to 25% of patients report persistent SD, and approximately one-third of patients describe the appearance of de novo SD. The use of PDE-5 inhibitors has been reported in post-renal transplant recipients with ED and no drug interactions with immunosuppressants or side effects have been observed.

Side effects of PDE inhibitors
PDE5 inhibitors are generally well tolerated in the treatment of ED[1]. The most common reported adverse drug reactions include headaches, back pain, myalgia, flushing, nasal congestion, sore throat, and dyspepsia. In general, the pain is of mild to moderate severity, typically occurring 12-24 h post-administration and usually resolving within 48 h, with or without medical treatment, such as acetaminophen.

Studies of HVPG changes with PDE-5 inhibitors
In one study[14], higher MELD scores and higher HVPG values were found in patients with ED. PDE-5 inhibitors have been administered to lower portal pressure in cirrhosis but the results are conflicting[1, 43-48] (Table 2).

CONCLUSION
Sexual dysfunction in liver diseases is one of the most ignored health issues and more prospective studies on this issue are needed which is potentially treatable. In particular, PDE inhibitors, especially tadalafil, are helpful for ED, and in females, treatment is multifactorial. Adequate control of primary liver diseases and causative agents of SD is warranted. All patients with liver diseases and cirrhosis should be evaluated, as SD is modifiable and treatable, and results in improved quality of life. More prospective and randomized controlled trials are needed on this topic, to understand the global epidemiology of the disease burden, possible underlying mechanisms, particularly related to non-hormonal aspects and sarcopenia, and possible newer treatment options.
Jagdish RK. SD and their treatment in liver diseases

FOOTNOTES

Author contributions: Jagdish RK developed the protocol, conceived, and wrote the literature review, and produced the tables and figures in the manuscript.

Conflict-of-interest statement: All the author declares no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: India

ORCID number: Rakesh Kumar Jagdish 0000-0001-7597-6890.

S-Editor: Liu JH
L-Editor: Webster JR
P-Editor: Liu JH

REFERENCES


Ther 2006; 23: 121-128 [PMID: 16393289 DOI: 10.1111/j.1365-2036.2006.02735.x]


